Supernus Pharmaceuticals, Inc., a Rockville, MD-based specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, recently closed two transactions through which it raised $42m.
The sale of its TCD Royalty Subsidiary, which was established in April 2008 to securitize royalties that were generated by Sanctura XR® and Oracea®, generated $27m, while the second transaction, the issuance of venture debt, generated $15m.
The company intends to use the proceeds from the transactions to prepare for the commercial launch of its two lead product candidates in epilepsy and to further the development of its pipeline designed to treat central nervous system (CNS) diseases.
Led by President and CEO Jack Khattar, Supernus is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy and ADHD including ADHD patients with impulsive aggression. Candidates include:
– SPN-538 (extended-release topiramate) and SPN-804 (extended-release oxcarbazepine) for epilepsy,
– SPN-810 for impulsive aggression in ADHD and
– SPN-812 for ADHD.